So excited to have our company highlighted along with our comrade Healthplus.ai! Cohort 10 is here to change how diagnosis is done!
The predictive and diagnostic tools created by Class 10 address some of the most prevalent problems for everyday patients. Today, we are excited to introduce Healthplus.ai and Hera Biotech. Healthplus.ai is enabling proactive surgery care through personalized complication predictions. Healthplus.ai's CE IIa certified solution, PERISCOPE®, is an AI-based decision support tool that highly-accurately predicts infection risks using existing EHR data, facilitating early intervention, eliminating unnecessary hospital stays, and reducing readmissions. Healthplus.ai uses real-time data along with validated & locally recalibrated machine learning algorithms to integrate with the existing workflow to aid clinical staff, delivering proactive and individualized care. Hera Biotech offers the world’s first non-surgical test for endometriosis, the number one cause of female infertility. Hera's test, MetriDx™, provides definitive diagnosis and staging of endometriosis through tissue-based analysis. MetriDx™ measures the expression patterns of an endometriosis-specific gene panel. Hera Biotech's patent-protected panel is heavily based on the expression profiles of a gene set implicated in a number of other invasive processes. Hera Biotech primarily serves the OB/GYN and fertility solutions markets with its innovative diagnostic tool. #CSaccelerator #healthinnovate #healthaccelerator #HIT #healthdisruptors #CSAclass10